Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by (12,150)

Items 1,501–1,600 of 12,150

1. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis
   Karoline Droebner, Mira Pavkovic, Manuel Grundmann, Elke Hartmann, Laura Goea, Johannes Nordlohne, Jürgen Klar, Frank Eitner, Peter Kolkhof · 2021 · American Journal of Nephrology
2. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
   Simke W. Waijer, Priya Vart, David Z.I. Cherney, Glenn Matthew Chertow, Niels Jongs, Anna Maria Langkilde, Johannes F.E. Mann, Ofri Mosenzon, John J.V. McMurray, Peter R Rossing et al. · 2022 · Diabetologia
3. Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
   Jay Patel, Negin Rassekh, Gregg C. Fonarow, PRAKASH C. DEEDWANIA, Farooq H. Sheikh, Ali Ahmed, Phillip Hong Lam · 2023 · Drugs
4. Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure
   Adriana Marton, Seyed Ehsan Saffari, Manfred Rauh, Ruo-Ning Sun, Armin Michael Nagel, Peter R Linz, Tzy Tiing Lim, Kaoru Takase‐Minegishi, Anastacia Pajarillaga, Sharon Saw et al. · 2024 · Journal of the American College of Cardiology
5. Insulin Resistance, Obesity, and Lipotoxicity
   Dilek Yazıcı, Selin Çakmak Demir, Havva Sezer · 2024 · Advances in experimental medicine and biology
6. Medical Management of Diabesity: Do We Have Realistic Targets?
   Joseph M Pappachan, Ananth Viswanath · 2017 · Current Diabetes Reports
7. Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
   on behalf of the EMPA-REG OUTCOME® investigators, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Uwe Hehnke, Jyothis Thomas George, Odd Erik Johansen, DAVID H. FITCHETT · 2018 · Diabetologia
8. Inhibition of Akt/mTOR/p70S6K Signaling Activity With Huangkui Capsule Alleviates the Early Glomerular Pathological Changes in Diabetic Nephropathy
   Wei Wu, Wei Hu, Wen-Bei Han, Yinglu Liu, Yue Tu, Haiming Yang, Qi‐Jun Fang, Mo-Yi Zhou, Zi-Yue Wan, Renmao Tang et al. · 2018 · Frontiers in Pharmacology
9. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
   Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati · 2019 · Intern J Endocrinol Metab
10. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a glp-1ra or to basal insulin plus an SGLT2 inhibitor: Beyond, a randomized, pragmatic trial
    Giugliano, Dario, Longo, Miriam, Caruso, Paola, Di Fraia, Rosa, Scappaticcio, Lorenzo, Gicchino, Maurizio, Petrizzo, Michela, Bellastella, Giuseppe, Maiorino, Maria Ida, Esposito, Katherine · 2021 · Diabetes Care
11. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
    Lu, Qingguo, Li, Xuan, Liu, Jia, Sun, Xiaodong, Rousselle, Thomas, Ren, Di, Tong, Nanwei, Li, Ji · 2019 · Bioscience Reports
12. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis
    Seidu, Samuel, Kunutsor, Setor K., Cos, Xavier, Gillani, Syed, Khunti, Kamlesh · 2018 · Primary Care Diabetes
13. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes
    Eberhard Standl, Oliver Schnell, Darren K. McGuire, Antonio Ceriello, Lars Rydén · 2017 · The Lancet Diabetes & Endocrinology
14. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
    Francesco Prattichizzo, Lucia La Sala, Lars Rydén, Nikolaus Marx, Marc Ferrini, Paul Elie Valensi, Antonio Ceriello · 2019 · European Journal of Preventive Cardiology
15. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial
    Norbert Joachim Tripolt, Ewald Kolesnik, Peter N. Pferschy, Nicolas Verheyen, Klemens Ablasser, Sandra Sailer, Hannes Franz Alber, Rudolf Berger, Carl Kaulfersch, Katharina Leitner et al. · 2019 · American Heart Journal
16. Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2
    Francesco Maranta, Lorenzo Cianfanelli, Domenico Cianflone · 2020 · Advances in experimental medicine and biology
17. Increased Glucose Availability Attenuates Myocardial Ketone Body Utilization
    Manoja Kumar Brahma, Chae‐Myeong Ha, Mark E. Pepin, Sobuj Mia, Zhihuan Sun, John C. Chatham, Kirk M. Habegger, E. Dale Abel, Andrew J. Paterson, Martin Elliot Young et al. · 2020 · Journal of the American Heart Association
18. SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
    Na Li, Hong Zhou · 2020 · Drug Design Development and Therapy
19. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
    Ann Wan-Chin Ling, Cze-Ci Chan, Shao‐Wei Chen, Yi‐Wei Kao, Chien-Ying Huang, Yi‐Hsin Chan, Pao‐Hsien Chu · 2020 · Cardiovascular Diabetology
20. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
    Matthias Rau, Kirsten Thiele, Niels‐Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P. Keszei, Michael Böhm, Nikolaus Marx, Michael Lehrke · 2021 · Cardiovascular Diabetology
21. SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
    Katrine Meyer Lauritsen, Bent R.R. Nielsen, Lars Poulsen Tolbod, Mogens Johannsen, Jakob Hansen, Troels Krarup Hansen, Henrik Wiggers, Niels Møller, Lars Christian Gormsen, Esben Søndergaard · 2020 · Diabetes
22. Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review
    Oliver T. Darlington, Carissa Dickerson, Marc Evans, Phil C. McEwan, Elisabeth Sörstadius, Daniel Sugrue, Heleen van Haalen, Juan José García Sánchez · 2021 · Advances in Therapy
23. Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
    Maximilian Trum, Johannes Riechel, Stefan Wagner · 2021 · International Journal of Molecular Sciences
24. Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
    Gloria M. Gager, Dirk von Lewinski, Harald Sourij, Bernd Jilma, Ceren Eyileten, KJ Filipiak, Martin Hülsmann, Jacek Kubica, Marek A Postula, Jolanta Maria Siller-Matula · 2021 · Biomedicine & Pharmacotherapy
25. Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
    Jin Sok Yu, Seung-Hwan Lee, Mee Kyoung Kim · 2022 · Endocrinology and Metabolism
26. Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes
    Morgan Erika Grams, Nigel J. Brunskill, Shoshana H. Ballew, Yingying Sang, Josef Coresh, Kunihiro Matsushita, Aditya Surapaneni, Samira Bell, Juan Jesús Carrero, Gabriel Chodick et al. · 2022 · Diabetes Care
27. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus
    Maria Alba, John Xie, Albert Fung, Mehul G. Desai · 2016 · Current Medical Research and Opinion
28. Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic
    Rhodri King, Peter J. Grant · 2016 · Herz
29. Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics
    Masao Saotome, Takenori Ikoma, Prottoy Hasan, Yuichiro Maekawa · 2019 · International Journal of Molecular Sciences
30. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
    Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono et al. · 2020 · International Journal of Molecular Sciences
31. MECHANISMS IN ENDOCRINOLOGY: Regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions
    Kristy M. Heppner, Jenny Tong · 2014 · European Journal of Endocrinology
32. Challenging Issues in Clinical Trial Design
    Stuart Pocock, Tim C. Clayton, Gregg W. Stone · 2015 · Journal of the American College of Cardiology
33. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta‐analysis
    Man Guo, Jingya Ding, Jingsong Li, Jiying Wang, Ting Dan Zhang, Cuiping Liu, Wei Gang Huang, Yang Long, Chenlin Gao, Yong Xu · 2018 · Diabetes Obesity and Metabolism
34. S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter
    Anke Bahrmann, Philipp Bahrmann, Jeannette Baumann, Jürgen Martin Bauer, Elke Brückel, M. Dreyer, M. Freitag, Alexander Friedl, Stefan Gölz, Susanne Grundke et al. · 2018 · Diabetologie und Stoffwechsel
35. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?
    Carlos G. Santos‐Gallego, Álvaro García‐Ropero, DONNA M. MANCINI, Sean Pinney, Johanna Contreras, Icilma V. Fergus, Vivian M. Abascal, Pedro Moreno, Farah Atallah-Lajam, Ronald Tamler et al. · 2019 · Cardiovascular Drugs and Therapy
36. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
    Vjera Ninčević, Tea Omanović Kolarić, Hrvoje Roguljić, Tomislav Kizivat, Martina Smolić, Ines Bilić-Čurčić · 2019 · International Journal of Molecular Sciences
37. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
    Kim Alexander Connelly, Yanling Zhang, Jean‐François Desjardins, Linda Nghiem, Aylin Visram, Sri Nagarjun Batchu, Veera Ganesh Yerra, Golam Kabir, Kerri Thai, Andrew Advani et al. · 2020 · Cardiovascular Diabetology
38. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
    Kazuomi Kario, Keith C. Ferdinand, James Henry O’Keefe · 2020 · Progress in Cardiovascular Diseases
39. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
    Louise A. Donnelly, John Dennis, Ruth L. Coleman, Naveed A. Sattar, Andrew Tym Hattersley, Rury R. Holman, Ewan R. Pearson · 2020 · Diabetes Care
40. Mechanisms and Models in Heart Failure
    Douglas L. Mann, Gary Michael Felker · 2021 · Circulation Research
41. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study
    Kirsten Thiele, Matthias Rau, Niels‐Ulrik Korbinian Hartmann, Julia Möllmann, Joachim Jankowski, Michael Böhm, András P. Keszei, Nikolaus Marx, Michael Lehrke · 2021 · Diabetes Obesity and Metabolism
42. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
    Lucia Leccisotti, Francesca Cinti, Gian Pio Sorice, Domenico D’Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Shawn Gugliandolo, Camilla Cocchi, Umberto Capece et al. · 2022 · Cardiovascular Diabetology
43. NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy
    Lixia Zhang, Chenchen Ai, Ming Bai, Jinglei Niu, Zheng Zhang · 2022 · International Journal of Molecular Sciences
44. Prevention of cardiorenal complications in people with type 2 diabetes and obesity
    Daniel J. Drucker · 2024 · Cell Metabolism
45. Developing Treatments for Chronic Kidney Disease in the 21st Century
    Matthew Douglas Breyer, Katalin Suszták · 2016 · Seminars in Nephrology
46. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
    Mulder, Skander, Heerspink, Hiddo J. L., Darshi, Manjula, Kim, Jiwan J., Laverman, Gozewijn D., Sharma, Kumar, Pena, Michelle J. · 2019 · Diabetes, Obesity and Metabolism
47. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
    Lin, Chen-Hsiu, Shao, Li, Zhang, Yu-Mei, Tu, Yu-Ju, Zhang, Yuzhen, Tomlinson, Brian, Chan, Paul, Liu, Zhongmin · 2020 · Expert Opinion on Pharmacotherapy
48. Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence
    Marco Giuseppe Del Buono, Giulia Iannaccone, Roberto Scacciavillani, Salvatore Carbone, Massimiliano Camilli, Giampaolo Niccoli, Barry A. Borlaug, Carl J. Lavie, Ross A Arena, Filippo Crea et al. · 2020 · Progress in Cardiovascular Diseases
49. The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients
    Simeon I. Taylor · 2020 · Diabetes Care
50. Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
    João Pedro Ferreira, Silvio E. Inzucchi, Michaela Mattheus, Thomas W. Meinicke, Dominik Steubl, Christoph Wanner, Bernard Zinman · 2021 · Diabetes Obesity and Metabolism
51. Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
    Ning Li, Dan Lv, Zhu X, Ping Wei, Yuan Gui, Shijia Liu, Enchao Zhou, Min Zheng, Dong Feng Zhou, Lu Zhang · 2021 · Frontiers in Medicine
52. Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells
    Cheol Ho Park, Bin Lee, Myeonggil Han, Woo Joong Rhee, Man Sup Kwak, Tae‐Hyun Yoo, Jeon‐Soo Shin · 2022 · Cell Death Discovery
53. Diabetic cardiomyopathy
    Ana Lorenzo-Almorós, J.M. Cepeda-Rodrigo, Óscar Lorenzo · 2020 · Revista Clínica Española (English Edition)
54. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis
    Siddhartha Dutta, Tarun Kumar, Surjit Singh, Sneha R. Ambwani, Jaykaran Charan, Shoban B. Varthya · 2022 · Journal of Family Medicine and Primary Care
55. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
    Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, Marta Belmonte, Emanuel Raschi, Guido Di Dalmazi, Sara Amicone, Lisa Canton, Damiano Fedele, Nicole Suma et al. · 2025 · Pharmacology & Therapeutics
56. New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease
    José Pedraza‐Chaverrí, Laura Gabriela Sánchez‐Lozada, Horacio Osorio‐Alonso, Edilia Tapia, Alexandra Scholze · 2016 · Oxidative Medicine and Cellular Longevity
57. Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?
    Paul D. Rosenblit · 2016 · Cardiovascular Diabetology
58. Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis
    Xiaoling Cai, Liwei Ji, Yifei Chen, Wenjia Yang, Lingli Zhou, Xueyao Han, Simin Zhang, Linong Ji · 2017 · Journal of Diabetes Investigation
59. Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy
    Masanori Wakisaka, T Nagao · 2017 · Glycobiology
60. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose‐lowering interventions
    Ronan Roussel, Philippe Gabríel Steg, Kamel Mohammedi, Michel Marre, Louis Potier · 2017 · Diabetes Obesity and Metabolism
61. HbA1c method performance: The great success story of global standardization
    Emma English, Erna Lenters‐Westra · 2018 · Critical Reviews in Clinical Laboratory Sciences
62. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
    Sempastian Filippas-Ntekouan, Vasilis Tsimihodimos, Theodosios D. Filippatos, Theodora Dimitriou, Moses Elisaf · 2018 · Expert Opinion on Drug Metabolism & Toxicology
63. Empagliflozin restores the integrity of the endothelial glycocalyx in vitro
    Scott Cooper, Hwee Teoh, Marc-Antoine Campeau, Subodh Verma, Richard L. Leask · 2019 · Molecular and Cellular Biochemistry
64. Heart Failure with Mid-Range Ejection Fraction: Characterization of Patients from the PINNACLE Registry®
    Nasrien E. Ibrahim, Yang Song, Christopher Paul Cannon, Gheorghe D. Doros, Patrícia A. Russo, Angelo Ponirakis, Claire C. Alexanian, James L. Januzzi · 2019 · ESC Heart Failure
65. Renal physiology of glucose handling and therapeutic implications
    David Z.I. Cherney, Mehmet Kanbay, Julie A. Lovshin · 2019 · Nephrology Dialysis Transplantation
66. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
    Bray, Jonathan J.H., Foster-Davies, Harri, Stephens, Jeffrey W. · 2020 · Diabetes Research and Clinical Practice
67. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
    Garg, Satish K., Akturk, Halis K., Kaur, Gurleen, Beatson, Christie, Snell-Bergeon, Janet · 2024 · Diabetes Technology & Therapeutics
68. Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
    Behnammanesh, Ghazaleh, Durante, Zane E., Peyton, Kelly J., Martinez-Lemus, Luis A., Brown, Scott M., Bender, Shawn B., Durante, William · 2019 · Frontiers in Pharmacology
69. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.
    Weng, Wayne, Tian, Ye, Kong, Sheldon X., Ganguly, Rahul, Hersloev, Malene, Brett, Jason, Hobbs, Todd · 2019 · Endocrinology, Diabetes & Metabolism
70. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
    Gallwitz, Baptist, Giorgino, Francesco · 2021 · Frontiers in Endocrinology
71. GLP-1 receptor agonists and heart failure in diabetes
    André Jacques Scheen · 2017 · Diabetes & Metabolism
72. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
    Alaaeldin M. Bashier, Azza Khalifa Bin Hussain, Elamin Abdelgadir, Fatheya Alawadi, Hani Mohamed Sabbour, ROBERT J. CHILTON · 2019 · Diabetology & Metabolic Syndrome
73. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study
    Salvatore Carbone, Hayley Billingsley, Justin McNair Canada, Edoardo Bressi, Brando Rotelli, Dinesh Kadariya, Dave L. Dixon, Roshanak Markley, Cory Ross Trankle, Richard H. Cooke et al. · 2020 · Diabetes/Metabolism Research and Reviews
74. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
    Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi et al. · 2020 · Cardiovascular Diabetology
75. Metabolic Consequences of Solid Organ Transplantation
    Mamatha Bhat, Shirine E. Usmani, Amirhossein Azhie, Minna Woo · 2020 · Endocrine Reviews
76. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
    Sang Youl Rhee, Jeong-Woo Lee, Hyewon Nam, Dae‐Sung Kyoung, Dong Wook Shin, Dae Jung Kim · 2021 · Diabetes & Metabolism Journal
77. Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis
    Kasper Bruun Kristensen, Daniel Pilsgaard Henriksen, Jesper Hallas, Anton Pottegård, Lars Christian Lund · 2021 · Diabetologia
78. Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Ran Wei, Weihao Wang, Qi Pan, Lixin Guo · 2022 · Frontiers in Endocrinology
79. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
    Massar Omar, Jesper Jensen, Caroline Kistorp, Kurt Højlund, Lars Melgaard Videbæk, Christian Tuxen, Julie Hempel Larsen, Camilla Fuchs Andersen, Finn Gustafsson, Lars Køber et al. · 2022 · Cardiovascular Diabetology
80. Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
    Ren Jie Phang, Rebecca Helen Ritchie, Derek John Hausenloy, Jarmon G. Lees, Shiang Yong Lim · 2022 · Cardiovascular Research
81. Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function
    Jinwu Wang, Xinyuan Huang, Hanjie Liu, Yuhang Chen, P. Li, Lingling Liu, Jiashen Li, Yangxi Ren, Junping Huang, Erya Xiong et al. · 2022 · Oxidative Medicine and Cellular Longevity
82. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
    Patrick Barry Mark, Pantelis A. Sarafidis, Robert Ekart, Charles Joseph Ferro, Olga C. Balafa, Beatriz Fernández‐Fernández, William Guy Herrington, Patrick Rossignol, Lucia Del Vecchio, José Manuel Valdivielso et al. · 2023 · Nephrology Dialysis Transplantation
83. Comprehensive advancements in the prevention and treatment of diabetic nephropathy: A narrative review
    Chukwuka Elendu, Minichimso John Okah, Kemeasoudei J.D. Fiemotongha, Adeyemo I. Boluwatife, Blessing N. Bassey, Eunice Omeludike, Babajide T. Obidigbo · 2023 · Medicine
84. Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure
    Genjiro Kimura · 2016 · Circulation Journal
85. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
    Robert M Bell, Derek M. Yellon · 2017 · The Lancet Diabetes & Endocrinology
86. Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy
    André C. Carpentier · 2018 · Canadian Journal of Cardiology
87. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr type 1 diabetic mice
    Annas Al‐Sharea, Andrew James Murphy, Lesley Ann Huggins, Y. Hu, Ira J. Goldberg, Prabhakara R. Nagareddy · 2018 · Atherosclerosis
88. Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
    David Polidori, Hiroaki Iijima, Maki Goda, Nobuko Maruyama, Nobuya Inagaki, Peter A. Crawford · 2018 · Diabetes Obesity and Metabolism
89. Liraglutide and Renal Outcomes in Type 2 Diabetes
    Johannes F.E. Mann, David D Ørsted, John B. Buse · 2017 · New England Journal of Medicine
90. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study
    Eu Jeong Ku, Dong‐Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh · 2019 · Diabetes Research and Clinical Practice
91. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease
    Sneha Kothari, Hiteshi Dhami-Shah, Samir R. Shah · 2019 · Journal of Clinical and Experimental Hepatology
92. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus
    Abhinav Sharma, Subodh Verma · 2019 · Canadian Journal of Diabetes
93. Post-Transplantation Diabetes Mellitus
    Syed Haris Ahmed, Kathryn Biddle, Titus Augustine, Shazli Azmi · 2020 · Diabetes Therapy
94. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
    Scheen, A.J. · 2016 · Diabetes & Metabolism
95. No disparity of the efficacy and all‐cause mortality between Asian and non‐Asian type 2 diabetes patients with sodium–glucose cotransporter 2 inhibitors treatment: A meta‐analysis
    Cai, Xiaoling, Gao, Xueying, Yang, Wenjia, Chen, Yifei, Zhang, Simin, Zhou, Lingli, Han, Xueyao, Ji, Linong · 2018 · Journal of Diabetes Investigation
96. Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease
    Mancini, G.B. John, Farkouh, Michael E., Brooks, Maria M., Chaitman, Bernard R., Boden, William E., Vlachos, Helen, Hartigan, Pamela M., Siami, Flora S., Sidhu, Mandeep S., Bittner, Vera et al. · 2016 · Journal of the American College of Cardiology
97. Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
    David M. Williams, Asif Nawaz, Marc Evans · 2019 · Diabetes Therapy
98. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
    Da-Peng Zhang, Li Xu, Lefeng Wang, Hong-Jiang Wang, Feng Jiang · 2020 · Cardiovascular Diabetology
99. Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease
    Devang M. Patel, Madhura Bose, Mark Emmanuel Cooper · 2020 · International Journal of Molecular Sciences
100. Morphological characteristics in diabetic cardiomyopathy associated with autophagy
     Hiromitsu Kanamori, Genki Naruse, 吉田明弘, Shingo Minatoguchi, Takatomo Watanabe, Tomonori Kawaguchi, Toshiki Tanaka, Yoshihisa Yamada, Hironobu Takasugi, Atsushi Mikami et al. · 2020 · Journal of Cardiology